CORE--CANCER PREVENTION BIOMARKERS

$128,658P30FY2008CANIH

Fox Chase Cancer Center, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567 Paper 39602533 Paper 39554190 Paper 39546469 Paper 39521739 Paper 39514554 Paper 39371220 Paper 39345610 Paper 39343653 Paper 39223207 Paper 39207123 Paper 39189642 Paper 39148468 Paper 39137728 Paper 39072643 Paper 39060143 Paper 39013784 Paper 39003201 Paper 38982062 Paper 38976159 Paper 38963567 Paper 38914477 Paper 38871720 Paper 38865671 Paper 38853421 Paper 38835516 Paper 38815457 Paper 38811332 Paper 38798370 Paper 38766032 Paper 38747616 Paper 38678525 Paper 38659828 Paper 38639476 Paper 38638131 Paper 38600381 Paper 38586274 Paper 38586042 Paper 38559274 Paper 38547779 Paper 38539515 Paper 38464238 Paper 38452871 Paper 38432028 Paper 38421650 Paper 38377387 Trial NCT04290585 Trial NCT03177057 Trial NCT02594826 Trial NCT02132884 Trial NCT02132858 Trial NCT02132845 Trial NCT02110953 Trial NCT02092714 Trial NCT02050009 Trial NCT01982591 Trial NCT01962948 Trial NCT01934179 Trial NCT01840150 Trial NCT01462630 Trial NCT01316757 Trial NCT01212822 Trial NCT00750009 Trial NCT00509626 Trial NCT00458588 Trial NCT00436397 Trial NCT00433524 Trial NCT00084591 Trial NCT00084539 Trial NCT00084526 Trial NCT00084513 Trial NCT00066677 Trial NCT00062322 Trial NCT00062309 Trial NCT00043108 Trial NCT00039520 Trial NCT00039507 Trial NCT00022308 Trial NCT00021398 Trial NCT00021372 Trial NCT00021346 Trial NCT00021333 Trial NCT00021320 Trial NCT00005037 Trial NCT00003264 Trial NCT00003263 Trial NCT00003109 Patent 9533040 Patent 9182383 Patent 9101603 Patent 8980258 Patent 8685658 Patent 8609437 Patent 8580263 Patent 8329873 Patent 7332585 Patent 7332580 Patent 7129057 Patent 6946275 Patent 6617427

Abstract

The identification of biomarkers of cancer risk, treatment response and progression, including genetic polymorphisms, epigenetic alterations, infectious agents and aberrant levels of proteins, hormones and nutrients has become an increasingly important aim of investigators with peer-reviewed funding at Fox Chase Cancer Center (FCCC), The Cancer Prevention Biomarker and Genotyping Facility (CPBGF) was established in 2001 as a developing Core Facility and provides a centralized resource for cost-effective genotyping services and biomarker assays to support research-based human population and mouse studies. Genotyping services include the analysis of polymorphic variation and mutations within normal or tumor DMA utilizing state-of-the-art instrumentation and technology. Assessment of host genotype and tissue-specific alterations in DNA sequence aids in identifying predictive genetic biomarkers of cancer risk and treatment response as well as surrogate endpoints for chemoprevention. Mouse genotyping services also aid researchers in the breeding and maintenance of their transgenic and knockout strains. In addition to genotyping, the Facility performs assays for the analysis of potential environmental and behavioral biomarkers of cancer risk (i.e., tobacco metabolites and bisphenol) as well as dietary factors, which can be measured in tissues and biofluids. This new Core Facility is directed by Cynthia Spittle, Ph.D. Since its inception in 2001, the Facility has provided services for a total of 18 FCCC investigators in six Research Programs in all three Divisions. In 2003, >94% of usage was from investigators with peer-reviewed funding. There has been >200% increase in the number of genotyping assays performed during the first three years of operation. The services provided by the CPBGF benefit clinicians, epidemiologists and behavioral scientists with interests in cancer prevention and pharmacogenetics research and basic scientists who utilize mouse models in their work. The demand for genotyping and biomarker analyses is expected to continue to grow over the next five years. The CPBGF offers distinctive and non-duplicative services that are a vital addition to the support offered to investigators with peer-reviewed funding. During the next five years, the CPBGF will expand its services, staffing, and infrastructure in a cost-effective manner in order to best meet the needs of investigators with peer-reviewed funding.

View original record on NIH RePORTER →